On Tuesday, 6 March 2018, Cristina Pucarinho, the Deputy Permanent Representative of Portugal to the United Nations made the following intervention at a UN briefing on Promoting Innovation and Access to Health Technologies in the Context of the Agenda 2030… Continue Reading →
KEI has appealed the NIH/NCI decision to proceed with the proposed exclusive license of anti-CD30 CAR T to Gilead, following an email of January 25, 2018 from Dr. David Lambertson of NCI rejecting all of KEI’s substantive suggestions and objections. KEI… Continue Reading →
Posted August 27, 2011 These are some tools for searching the US Department of State cables released by Wikileaks. A Wikileaks page on the cables is available here: http://wlcentral.org/cablegate KEI recommends this site for searching the cables by key words:… Continue Reading →
On February 14, the NIH was asked what the budget was for the Phase 1 clinical trial of the anti-CD30 CAR T technology that is the subject of a proposed exclusive patent license to Kite/Gilead. The clinicaltrials.gov identifier for the… Continue Reading →
2007 2007: Letter to Senators on Public Access Act 2012 2012: Representatives Issa (R-CA) and Maloney (D-NY) introduce anti-open access legislation
Signatures to the petition to President Obama, regarding transparency of ACTA Back to the petition US signatories Knowledge Ecology International David Bollier, Onthecommons.org U.S. Public Interest Research Group Essential Action Health Action International (HAI) Global Public Citizen Ellen Miller, Sunlight… Continue Reading →
The following is a letter that was sent on November 3, 2009 to President Obama, asking that the negotiations regarding ACTA be made more transparent. For more background on ACTA and the disputes over transparency, see KEI website on ACTA… Continue Reading →
The following is a letter that was sent on November 3, 2009 to President Obama, asking that the negotiations regarding ACTA be made more transparent. For more background on ACTA and the disputes over transparency, see KEI website on ACTA… Continue Reading →
This page features KEI blog posts, testimony, comments, and research on the transparency of the costs of research and development in the pharmaceutical sector. United States Transparency Legislation 16 March 2017: KEI testifies before a Maryland House of Delegates Subcommittee… Continue Reading →
In the area of Transparency, KEI works on several different topics, including for example: Norm setting. KEI has advocated access to meeting venues, timely disclosures of negotiating texts, and the use of webcasting of meetings, among other measures. Trade negotiations… Continue Reading →